How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,722 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. TSEB (...) and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02822586 Recruitment Status : Active, not recruiting First Posted : July 4, 2016 Last Update Posted : February 25, 2019 Sponsor: Virginia Commonwealth University Collaborator: Seattle Genetics

2016 Clinical Trials

162. Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2016 Clinical Trials

163. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. (PubMed)

Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor.To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL).Patients received quisinostat 8 mg or 12 mg on days 1, 3 and 5 of each week in 21-day treatment cycles

2016 British Journal of Dermatology

164. Biopsy correlation of surface area vs single axis measurements on CT scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sezary syndrome. (PubMed)

Biopsy correlation of surface area vs single axis measurements on CT scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sezary syndrome. 28012157 2018 08 13 2018 08 13 1365-2133 177 3 2017 09 The British journal of dermatology Br. J. Dermatol. Biopsy correlation of surface area vs. single-axis measurements on computed tomography scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sézary syndrome. 877-878 10.1111/bjd.15266 Haththotuwa R R Department (...) . Shah F F Department of Dermatology, University Hospitals Birmingham, Birmingham, U.K. Chaganti S S Department of Haematology, University Hospitals Birmingham, Birmingham, U.K. Scarisbrick J J Department of Dermatology, University Hospitals Birmingham, Birmingham, U.K. eng Letter 2017 07 31 England Br J Dermatol 0004041 0007-0963 IM Biopsy Dermatitis, Exfoliative pathology Humans Lymph Nodes pathology Lymphatic Metastasis Mycosis Fungoides pathology Retrospective Studies Sezary Syndrome pathology

2016 British Journal of Dermatology

165. Mycosis fungoides staged by 18F-flurodeoxyglucose positron emission tomography/computed tomography: Case report and review of literature. (PubMed)

Mycosis fungoides staged by 18F-flurodeoxyglucose positron emission tomography/computed tomography: Case report and review of literature. Mycosis fungoides is a kind of malignant lymphoma arising from T cells, but primarily occurs in skin, and it is the most common type of cutaneous lymphoma. Mycosis fungoides (MF) is a rare non-Hodgkin lymphoma but the most common type of primary cutaneous T-cell lymphomas. Because of unknown etiology and mechanism, and lack of typical clinical

Full Text available with Trip Pro

2016 Medicine

166. The biomarker landscape in mycosis fungoides and sézary syndrome. (PubMed)

The biomarker landscape in mycosis fungoides and sézary syndrome. The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome

Full Text available with Trip Pro

2016 Experimental Dermatology

167. Mycosis fungoides patient accompanied actinic keratosis, actinic keratosis with squamous cell carcinoma transformation, and porokeratosis after NBUVB therapy - 1st case report and review of the literature. (PubMed)

Mycosis fungoides patient accompanied actinic keratosis, actinic keratosis with squamous cell carcinoma transformation, and porokeratosis after NBUVB therapy - 1st case report and review of the literature. Mycosis fungoides (MF) is the most common form of primary cutaneous T cell lymphoma. Narrowband ultraviolet B light (NBUVB) is used increasingly in treating MF because of its good toleration and well-established management.To discuss the risk factors and underlying pathogenic factors

Full Text available with Trip Pro

2016 Medicine

168. Mycosis Fungoides two decades after exposure to sulfur mustard: A follow up of 1100 victims. (PubMed)

Mycosis Fungoides two decades after exposure to sulfur mustard: A follow up of 1100 victims. Sulphur mustard (SM) is an alkylating chemical warfare agent which causes acute and chronic injuries to the eyes, skin, lung and respiratory tract.We aimed to investigate the relationship between SM poisoning and Mycosis fungoides (MF) as a late consequence.In this retrospective study, the medical files of 1100 Iranian veterans confirmed to have exposure to SM agent during the Iraq-Iran war of the 1980s

2016 Journal of the European Academy of Dermatology and Venereology

169. Perineural and intraneural cutaneous granulomas in granulomatous mycosis fungoides mimicking tuberculoid leprosy. (PubMed)

Perineural and intraneural cutaneous granulomas in granulomatous mycosis fungoides mimicking tuberculoid leprosy. Histological similarities between granulomas and granulomatous mycosis fungoides (GMF) may lead to misdiagnoses of sarcoidosis or leprosy.This report presents four patients with GMF in whom skin biopsies showed perineural and intraneural granulomas that were confused with tuberculoid leprosy granulomas.Patient 1 presented with erythematous plaques and bulky nodules. Biopsy findings

2016 International Journal of Dermatology

170. The new Cutaneous Lymphoma International Prognostic index (CLIPi) for early mycosis fungoides failed to identify prognostic groups in a cohort of Spanish patients. (PubMed)

The new Cutaneous Lymphoma International Prognostic index (CLIPi) for early mycosis fungoides failed to identify prognostic groups in a cohort of Spanish patients. 26990536 2017 08 22 2017 08 22 1365-2133 175 4 2016 Oct The British journal of dermatology Br. J. Dermatol. The new Cutaneous Lymphoma International Prognostic index (CLIPi) for early mycosis fungoides failed to identify prognostic groups in a cohort of Spanish patients. 794-6 10.1111/bjd.14559 Sanz-Bueno J J Department (...) and over Disease Progression Female Humans Kaplan-Meier Estimate Male Middle Aged Mycosis Fungoides diagnosis mortality Prognosis Risk Assessment methods Severity of Illness Index Skin Neoplasms diagnosis mortality Spain epidemiology Young Adult 2016 3 19 6 0 2016 3 19 6 0 2017 8 23 6 0 ppublish 26990536 10.1111/bjd.14559

2016 British Journal of Dermatology

171. Immunophenotypic shift from CD4<sup>+</sup> to CD8<sup>+</sup> in mycosis fungoides. (PubMed)

Immunophenotypic shift from CD4+ to CD8+ in mycosis fungoides. 27167533 2017 08 22 2017 08 22 1365-2133 175 4 2016 Oct The British journal of dermatology Br. J. Dermatol. Immunophenotypic shift from CD4(+) to CD8(+) in mycosis fungoides. 830-3 10.1111/bjd.14723 Endo C C Department of Dermatology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. Naka Y Y Department of Dermatology, Tokyo Women's Medical University, 8-1 Kawada-cho (...) , Japan. Tsunemi Y Y Department of Dermatology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. ytsun-tky@umin.ac.jp. eng Case Reports Letter 2016 07 27 England Br J Dermatol 0004041 0007-0963 IM CD4-Positive T-Lymphocytes immunology CD8-Positive T-Lymphocytes immunology Humans Immunophenotyping Male Middle Aged Mycosis Fungoides immunology Skin Neoplasms immunology 2016 5 12 6 0 2016 5 12 6 0 2017 8 23 6 0 ppublish 27167533 10.1111/bjd.14723

2016 British Journal of Dermatology

172. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting. (PubMed)

Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting. Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of rare non-Hodgkin lymphomas that arise in the skin. In advanced stages, CTCL becomes systemic and is associated with poor prognosis. Diagnosis of CTCL and treatment of early-stage disease with topical therapies often occurs under the care of a dermatologist. Community oncologists see few

Full Text available with Trip Pro

2016 Critical reviews in oncology/hematology

173. Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. (PubMed)

Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. Large case series suggest that patients with folliculotropic mycosis fungoides (FMF) have a worse prognosis than patients with classic mycosis fungoides (MF). However, recent studies described a subgroup of patients with FMF with a more favorable prognosis. Distinction between indolent and aggressive FMF may have important therapeutic consequences but is hampered by the inability of the current tumor-node-metastasis

Full Text available with Trip Pro

2016 JAMA dermatology (Chicago, Ill.)

174. Interstitial Mycosis Fungoides: A Clinicopathologic Study of 21 Patients. (PubMed)

Interstitial Mycosis Fungoides: A Clinicopathologic Study of 21 Patients. Interstitial mycosis fungoides (IMF) is a rare histopathologic variant of mycosis fungoides (MF) that may mimic other inflammatory dermatoses, mainly interstitial granuloma annulare, inflammatory morphea, and interstitial granulomatous dermatitis. Only small series and sporadic case reports of IMF have been described in the literature. We reviewed 27 specimens from 21 patients with IMF (M:F=11:10, median age 60) to better

2016 American Journal of Surgical Pathology

175. New insights into folliculotropic mycosis fungoides (FMF): A single-center experience. (PubMed)

New insights into folliculotropic mycosis fungoides (FMF): A single-center experience. It is generally accepted that folliculotropic mycosis fungoides (FMF) is usually typified by indurated plaques and tumors mainly on the head/neck and an aggressive course. However, its clinical manifestations have long been recognized to be quite variable, and some studies indicate a better prognosis for certain presentations.We sought to summarize our experience with the clinicopathological presentations

2016 Journal of American Academy of Dermatology

176. Expression of SOX18 in Mycosis Fungoides. (PubMed)

Expression of SOX18 in Mycosis Fungoides. SOX18 is a transcription factor involved in the development of hair follicle, blood and lymphatic vessels, as well as regenerative processes. In addition, accumulated data indicate the role of SOX18 in tumourigenesis. So far, no studies on the role of SOX18 expression in mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma, have been performed. Therefore, we evaluated SOX18 expression in MF at the mRNA and protein level. SOX18

Full Text available with Trip Pro

2016 Acta Dermato-Venereologica

177. Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. Mycosis fungoides and Sézary syndrome (MF/SS) are rare cutaneous T-cell lymphomas. Their etiology is poorly understood.A pooled analysis of 324 MF/SS cases and 17217 controls from 14 case-control studies from Europe, North America, and Australia, as part of the International Lymphoma Epidemiology Consortium (InterLymph) Non

Full Text available with Trip Pro

2016 Journal of the National Cancer Institute. Monographs

178. Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor (PubMed)

Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor Mycosis fungoides (MF) is a cutaneous T-cell lymphoma that can undergo local progression with possible systemic dissemination. We report a case of a patient affected by MF with a pancreatic mass that was a diagnostic challenge between primitive tumor and pancreatic metastasis from MF. Clinical setting findings and imaging studies raised the suspicion of a pancreatic primary neoplasm. A diagnostic clue was provided

Full Text available with Trip Pro

2016 World Journal of Gastroenterology

179. Syringotropic mycosis fungoides responding well to VELP chemotherapy: A case report (PubMed)

Syringotropic mycosis fungoides responding well to VELP chemotherapy: A case report Mycosis fungoides (MF), a low-malignant lymphoproliferative disorder, is the most common type of cutaneous T-cell lymphoma. The current study reported a case of syringotropic MF, a rare variant of MF, which presented with reactive B cell proliferation, lymphoid follicle formation, hair loss and lymphadenopathy. The clinical manifestations of the patient were MF-like lumps. Immunohistochemical staining of AE1/AE3

Full Text available with Trip Pro

2016 Experimental and therapeutic medicine

180. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin (PubMed)

The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin The 2 histone deacetylase inhibitors (HDACIs) approved for the treatment of cutaneous T-cell lymphoma (CTCL) including mycosis fungoides/sezary syndrome (MF/SS), suberoylanilide hydroxamic acid (SAHA) and romidepsin, are associated with low rates of overall response and high rates of adverse effects. Data regarding combination treatments

Full Text available with Trip Pro

2016 PloS one

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>